Join Now

Category Archives: BioUtah News

Human Forms and Body Parts Trigger Strong Reactions in the Brain

By Natalie Themm | Published December 19, 2024

Human Forms and Body Parts Trigger Strong Reactions in the Brain

| Tagged | Comments Off on Human Forms and Body Parts Trigger Strong Reactions in the Brain

Canary Speech and Prism Care Announce Partnership to Enhance Extended Care Through Vocal Biomarker Technology

By Natalie Themm | Published December 19, 2024

Partnership aims to set new industry standards for managing mental health and cognitive conditions

| Tagged | Comments Off on Canary Speech and Prism Care Announce Partnership to Enhance Extended Care Through Vocal Biomarker Technology

SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS

By Natalie Themm | Published December 19, 2024

SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS

| Tagged | Comments Off on SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS

BD Resolves Previously Disclosed SEC Investigation

By Natalie Themm | Published December 19, 2024

BD has reached an agreement with the U.S. SEC to resolve the previously disclosed investigation related to prior public disclosures.

| Tagged | Comments Off on BD Resolves Previously Disclosed SEC Investigation

NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD

By admin | Published December 12, 2024

VALENCIA, Calif. – Dec. 3, 2024 – Nusano, a physics company transforming the production of radioisotopes, today announced the creation of a Medical Radioisotopes Advisory Board. This panel of internationally recognized leaders in nuclear medicine will provide strategic guidance to Nusano, ensuring its product development aligns with emerging trends and with the needs of cancer […]

| Comments Off on NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

By admin | Published December 12, 2024

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.’s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India. In support of the “Make […]

| Comments Off on Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

By admin | Published December 12, 2024

LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today promising topline data resulting in the advancement to the second stage of its Phase 2 clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk […]

| Comments Off on Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

By Natalie Themm | Published December 12, 2024

Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.

| Tagged | Comments Off on Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

CancerVax Targets Hard to Treat Pancreatic Cancer

By Natalie Themm | Published December 12, 2024

With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors

| Tagged | Comments Off on CancerVax Targets Hard to Treat Pancreatic Cancer

BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

By Natalie Themm | Published December 12, 2024

BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

| Tagged , | Comments Off on BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

By Natalie Themm | Published December 12, 2024

Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions

| Tagged | Comments Off on Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

By Natalie Themm | Published December 12, 2024

Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®

| Tagged | Comments Off on Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

A Special Thanks To Our Legacy and Platinum Elite Members